Company presentation, including background, services and expertise
Company presentation, including background, services and expertise
making the leap from bionano research
Quintain Consulting - Overview
Quintain Consulting Pty Ltd is a private firm, which offers services in the
area of bionanotechnology commercialisation
• Founded in July 2009 by Dr Bob Irving and
Dr Jeanette Pritchard
• Building on knowledge developed during time
at NVA and NanoVic, to offer expert guidance to
government and academic groups, companies
and investors who are involved in
• Over 40 years combined experience in
biotechnology and bionanotechnology
industries in Australia, UK & Canada
• Strategic Advice- For research, development, industrial
and government bodies who are involved or looking to
become involved in bionanotechnology product
development and want to increase their understanding of
local and worldwide markets and opportunities.
• Asset Management- For parties with large and small IP
• Technology Assessment- For funding and investment
groups / individuals who would like an expert opinion on
bionanotechnology opportunities being presented.
• Project and Process Management- Assembly and
management of multisector / multidisciplinary teams.
Management of product development and
commercialisation processes, including input into
Australian and US regulatory issues.
Dr Bob Irving Dr Jeanette Pritchard
Founder & Director Founder & Director
Bob has more than 25 years experience in diagnostic and Jeanette has 15 years experience working in device
therapeutic technology development in Australia, development, over 8 of which have been within the
Canada and the UK. He has led programs within CSIRO, biotechnology industry in the UK and Australia. Jeanette
Diagnostics CRCs and biotech companies worldwide and has extensive experience in project management, business
has been instrumental in the establishment and launch development and commercialisation of devices for rapid,
of start-up companies such as Evogenix. point-of-care disease detection and on-site water
Bob advises industry bodies and government on
nanotechnology strategy, development and Jeanette participates in the Victorian Government Skills and
commercialization, and participated in the Australian Public Support Working Group, as part of a broad initiative
Academy of Technological Sciences and Engineering to develop actions for implementation of the five year
mission to France, organised in association with the Biotechnology Strategic Plan.
National Academy of Technologies of France.
Jeanette completed her PhD at the University of Newcastle
Bob has a PhD through the Imperial Cancer Research upon Tyne (UK), with a research topic on development of a
Fund (London, UK) with a research topic on prostate detection system for cardiac marker proteins.
Commercialisation and management of InCellution IP, assigned from AdAlta Pty Ltd. The
InCellution process uses natural somatic hypermutation processes that occur in human B-cells
to produce improved diagnostic and therapeutic reagents. Currently in discussions with
overseas group and investors.
Engagement by NSW-based start-up diagnostics company BioDetectors Pty Ltd, to manage
its business development and commercialisation activities.
Trinity Bioactives / NanoVentures Australia
Management of the completion of the current phase of the meningococcal diagnostic test
Feasibility study of sensing and delivery devices currently being assessed by a medical
Case Study 1
Identification of Technologies and IP for Sensing and Delivery; Negotiation
and Coordination of Licenses and Assignments
Convenient systems (for both patient and healthcare providers) for
monitoring health/drug status and delivery of medications require
continuous monitoring, signaling and delivery devices with minimal
disruption to the patient.
Evaluated sensing systems in development and available commercially and gained
access to sensor IP developed within local university (RMIT). Proposed a sensing
and delivery solution to fulfill the needs of the client company. Negotiated License
and Assignment Agreements.
Licensing and Assignment Agreements for required technologies completed and
product development plan prepared.
Case Study 2
Licensing out Transdermal Delivery Technologies for large molecule
Each year in the US alone, 29,000 anaphylactic reactions to foods are treated in
emergency departments and nearly 200 deaths occur due to food
allergies. Seafood allergies are the most common cause, with life-threatening
reactions. Traditionally, anti-allergy or “tolerising” reagents are injected into
patients, but more direct access to the immune system is preferred.
Approach (through NVA):
Negotiated Co-Development and Licensing Agreement with the company, for the
evaluation and in vivo testing of the Formulation and Transdermal Patch delivery of
its anti-allergy therapeutic(s).
Successful license agreement negotiation and execution.
Managed development plan; coordinated the materials, formulation and testing of
Case Study 3
The pharmaceutical industry has a need for improved therapeutic and
diagnostic antibody-based reagents to provide better health outcomes for
As monoclonal and recombinant antibodies become increasingly accessible
to the clinic for treating a range of disease states including cancer, it is
becoming necessary for these reagents to be optimised for use in humans
and in their effectiveness.
Approach (through Diagnostics CRC):
Technologies and expertise in the UK, Germany and Australia were identified and
harnessed, and funding to support the team secured. IP was protected. Investment
funding was secured to develop the technology into a commercially relevant process.
The investment was used to establish a start-up company for this purpose.
The start-up company- EvoGenix- which successfully developed the commercial
process went to IPO and then merged with Peptech to form Arana. Arana has now has
been acquired by Cephalon (US).
Case Study 4
Develop an understanding and raise awareness of future diagnostics appropriate to
the Indonesian region
Improved next generation diagnostic technologies and tests developed in Australia
were of interest to researchers, clinicians and diagnostics companies in Indonesia.
They needed to have the opportunity to understand and evaluate their
applications and to make links with developers of the technologies and tests.
State of the Art equipment was readily available but not strategies or expertise for
Approach (through CSIRO):
Coordinated researchers from Institutions and Universities in Queensland and Victoria, along
with WHO and Australian Biotechnology Diagnostics Companies, with leaders in the Inter-
University Biotechnology Centres in Bandung and Yogyakarta, for a series of Indonesian
Two 2-day workshops with academic, applied scientists and clinicians from the Centres,
Universities and diagnostics companies from across Indonesia. Institutions in Australia
supported or provided access to Indonesian researchers for follow-up after the workshops.
1 Queens Road
Melbourne VIC 3004